FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2583904068> ?p ?o ?g. }

• W2583904068 abstract "Abstract Introduction: Patients with relapsed/refractory aggressive non-Hodgkins lymphoma have limited options for further therapy; ESHAP is an active regimen in these patients. Velasquez, et al. reported a 37% complete response and 27% partial response; however, the median duration of survival in this group of patients was 14 months. The addition of rituximab to CHOP improved outcomes in front-line therapy for NHL. Since there is no reported data on the safety and efficacy of ESHAP with rituximab, we have evaluated the combination in patients with relapsed/refractory aggressive lymphoma. Methods: The regimen consisted of: rituximab (375 mg/m2) given on days 1 and 6, standard ESHAP therapy (etoposide 40 mg/m2 IV/2h day 1–4; methylprednisolone 500 mg/m2 days 1–4; cytarabine 2 g/m2 IV/3h on day 5 and cisplatin 25 mg/m2 CIV days 1–4) on day 8. Rituximab was repeated prior to the third and fifth ESHAP cycle, followed by two additional doses of rituximab after cycle 6 of ESHAP. Cycles were repeated every 21 days. 13 patients enrolled in the study. Median age was 57 years (range 37–70); there were 11 males and 2 females. 10/13 (77%) of patients had advanced disease (stage III/IV). Histology was: Diffuse Large Cell Lymphoma in 12 patients (92%) and Mantle Cell Lymphoma in 1 patient (8%). 9 of 13 patients, according to the IPI, had intermediate or high risk disease. All patients had one or more of the following therapies: CHOP or CHOP-like regimens (with or without radiation therapy), CHOP with rituximab, fludarabine/rituximab or radioimmunotherapy. Results: Among the 13 patients enrolled, 6 patients completed all 6 cycles. Among these, 4 (66.6%) achieved a CR; 1 PR (16.7%) and 1 PD (16.7%); the overall response rate was 83%. 3 of 4 patients remain in a CR at a median of 48 months (range 46–51 months); 1 pt relapsed after 24 months. The remaining 7 patients received a median of 2 cycles: 1 patient received autologous peripheral blood stem cell transplantation after 3 cycles of therapy with 2.20 x 106/kg CD 34+ cells, 1 patient achieved a CR after 3 cycles for stage 1 disease and remains in a CR at 14 months, 1 patient achieved a CR after two cycles and was lost to follow up, and 1 patient achieved a CR after 3 cycles, however relapsed in five months. 3 patients had PD after cycle 1,1 and 2. 3 of 13 patients had received prior therapy with rituximab; 1 patient achieved a PR and went on to autologous peripheral blood stem cell transplantation, 1 patient achieved a CR of 5 month duration after 3 cycles, and 1 patient had progressive disease. There were five episodes of treatment-related delays in therapy. Two patients required dose reductions. There were three episodes of neutropenic fever. Conclusion: Without high dose therapy and stem cell transplantation, long term remission in relapsed/refractory aggressive NHL is rare. Our study represents the first reported data on the efficacy and safety of ESHAP and rituximab in this group of patients. This combination therapy leads to durable responses with acceptable toxicity and may be considered as a viable alternative therapy in patients who are not candidates for stem cell transplantation. In addition, after effective cytoreduction with ESHAP and Rituximab, stem cell collection was adequate in our patient who underwent autologous stem cell transplantation." @default.
• W2583904068 created "2017-02-10" @default.
• W2583904068 creator A5013922587 @default.
• W2583904068 creator A5024371415 @default.
• W2583904068 creator A5025499306 @default.
• W2583904068 creator A5054509815 @default.
• W2583904068 creator A5088142456 @default.
• W2583904068 date "2005-11-16" @default.
• W2583904068 modified "2023-09-28" @default.
• W2583904068 title "ESHAP with Rituximab Is Highly Efficacious with Durable Responses in Patients with Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma." @default.
• W2583904068 doi "https://doi.org/10.1182/blood.v106.11.4787.4787" @default.
• W2583904068 hasPublicationYear "2005" @default.
• W2583904068 type Work @default.
• W2583904068 sameAs 2583904068 @default.
• W2583904068 citedByCount "0" @default.
• W2583904068 crossrefType "journal-article" @default.
• W2583904068 hasAuthorship W2583904068A5013922587 @default.
• W2583904068 hasAuthorship W2583904068A5024371415 @default.
• W2583904068 hasAuthorship W2583904068A5025499306 @default.
• W2583904068 hasAuthorship W2583904068A5054509815 @default.
• W2583904068 hasAuthorship W2583904068A5088142456 @default.
• W2583904068 hasConcept C126322002 @default.
• W2583904068 hasConcept C141071460 @default.
• W2583904068 hasConcept C2776694085 @default.
• W2583904068 hasConcept C2778041864 @default.
• W2583904068 hasConcept C2778119113 @default.
• W2583904068 hasConcept C2778476033 @default.
• W2583904068 hasConcept C2779338263 @default.
• W2583904068 hasConcept C2779725641 @default.
• W2583904068 hasConcept C2780653079 @default.
• W2583904068 hasConcept C2781214270 @default.
• W2583904068 hasConcept C2781413609 @default.
• W2583904068 hasConcept C71924100 @default.
• W2583904068 hasConcept C90924648 @default.
• W2583904068 hasConceptScore W2583904068C126322002 @default.
• W2583904068 hasConceptScore W2583904068C141071460 @default.
• W2583904068 hasConceptScore W2583904068C2776694085 @default.
• W2583904068 hasConceptScore W2583904068C2778041864 @default.
• W2583904068 hasConceptScore W2583904068C2778119113 @default.
• W2583904068 hasConceptScore W2583904068C2778476033 @default.
• W2583904068 hasConceptScore W2583904068C2779338263 @default.
• W2583904068 hasConceptScore W2583904068C2779725641 @default.
• W2583904068 hasConceptScore W2583904068C2780653079 @default.
• W2583904068 hasConceptScore W2583904068C2781214270 @default.
• W2583904068 hasConceptScore W2583904068C2781413609 @default.
• W2583904068 hasConceptScore W2583904068C71924100 @default.
• W2583904068 hasConceptScore W2583904068C90924648 @default.
• W2583904068 hasLocation W25839040681 @default.
• W2583904068 hasOpenAccess W2583904068 @default.
• W2583904068 hasPrimaryLocation W25839040681 @default.
• W2583904068 hasRelatedWork W2006707835 @default.
• W2583904068 hasRelatedWork W2045828185 @default.
• W2583904068 hasRelatedWork W2077814737 @default.
• W2583904068 hasRelatedWork W2110119190 @default.
• W2583904068 hasRelatedWork W2114602553 @default.
• W2583904068 hasRelatedWork W2355835258 @default.
• W2583904068 hasRelatedWork W2583904068 @default.
• W2583904068 hasRelatedWork W2597446402 @default.
• W2583904068 hasRelatedWork W3006755138 @default.
• W2583904068 hasRelatedWork W3083231619 @default.
• W2583904068 isParatext "false" @default.
• W2583904068 isRetracted "false" @default.
• W2583904068 magId "2583904068" @default.
• W2583904068 workType "article" @default.